Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 11.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 212,842 shares of the company’s stock after selling 28,710 shares during the period. Wellington Management Group LLP’s holdings in Amylyx Pharmaceuticals were worth $3,823,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Landscape Capital Management L.L.C. boosted its position in shares of Amylyx Pharmaceuticals by 17.5% during the 4th quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock worth $148,000 after purchasing an additional 1,825 shares during the period. KBC Group NV purchased a new stake in Amylyx Pharmaceuticals in the first quarter valued at approximately $26,000. Meeder Asset Management Inc. purchased a new stake in Amylyx Pharmaceuticals in the fourth quarter valued at approximately $25,000. State of Wyoming acquired a new position in Amylyx Pharmaceuticals during the second quarter worth $40,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Amylyx Pharmaceuticals by 13.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company’s stock worth $326,000 after purchasing an additional 3,198 shares in the last quarter. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Gina Mazzariello sold 15,000 shares of the business’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the completion of the transaction, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 10.90% of the company’s stock.

Amylyx Pharmaceuticals Stock Down 4.4%

Shares of AMLX stock opened at $32.40 on Thursday. The firm has a 50 day moving average of $25.15 and a two-hundred day moving average of $18.62. The stock has a market capitalization of $3.61 billion, a PE ratio of -22.66 and a beta of -0.13. Amylyx Pharmaceuticals, Inc. has a 52 week low of $10.83 and a 52 week high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). Analysts expect that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AMLX has been the subject of a number of research reports. Wolfe Research raised Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Citigroup increased their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Mizuho raised their target price on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, August 18th. HC Wainwright lifted their target price on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $36.50.

About Amylyx Pharmaceuticals